Law Firm Probes Pacira BioSciences Over Shareholder Rights
Monteverde & Associates is investigating Pacira BioSciences amid shareholder concerns. The M&A-focused class action firm has recovered millions for investors.
A New York-based class action law firm has launched an investigation into Pacira BioSciences, Inc., the pharmaceutical company listed on the Nasdaq exchange under the ticker PCRX, according to an announcement released in October 2026.
Monteverde & Associates PC, led by class action attorney Juan Monteverde, disclosed the probe targeting the biosciences company. The firm, which describes itself as focused on mergers and acquisitions litigation, said it has previously recovered millions of dollars on behalf of shareholders in similar cases.
Read more Law Firm Probes Option Care Health Shareholder Rights (OPCH) →
The firm was recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, a ranking that evaluates plaintiffs' law firms active in securities litigation. The citation is frequently cited by class action attorneys as a credential when soliciting potential clients following corporate transactions or alleged misconduct.
Shareholder investigations of this type typically precede formal litigation and are often triggered by concerns over the fairness of a transaction, disclosures made to investors, or the conduct of a company's board of directors. No specific allegations or claims against Pacira BioSciences were detailed in the announcement beyond the firm's stated intent to investigate.
Investors holding shares of Pacira BioSciences who believe they may have claims are encouraged to seek independent legal counsel. Continue reading at All Financial Services & Investing.
